Sun Pharma Shares Jump 5% After $11.75 Billion Organon Acquisition, Marking Biggest Overseas Bet
Sun Pharmaceutical Industries has agreed to buy US drugmaker Organon in an all-cash deal valued at US$ 11.75 billion, in one of the biggest overseas acquisitions ever announced by an Indian company. The deal gives Organon shareholders US$ 14 per share and is expected to close in early 2027, subject to regulatory approvals and Organon shareholder consent.
Sun Pharma-Organon Deal: Key Details
| Particulars | Details |
|---|---|
| Acquiring Company | Sun Pharmaceutical Industries |
| Target Company | Organon |
| Deal Value | $11.75 Billion (including debt) |
| Deal Type | Full acquisition (100% stake) |
| Parent Origin of Organon | Merck & Co. |
| Key Segments | Women’s Health, Biosimilars, Established Medicines |
| Strategic Objective | Global expansion, portfolio diversification, specialty growth |
| Financing Method | Mix of debt and internal accrals |
| Regulatory Status | Pending approvals across multiple jurisdictions |
| Expected Closure Timeline | Likely within the next few quarters |
| Industry Impact | One of the largest overseas acquisitions by an Indian pharma company |
Sun Pharma’s biggest global bet yet
The acquisition marks a major step in Sun Pharma’s push to expand beyond its core generics business and deepen its presence in branded medicines, women’s health and biosimilars. Organon, based in the US, has a portfolio linked to women’s healthcare and established medicines, and Sun Pharma said the combination should create a stronger global platform.
The boards of both companies have approved the transaction, according to Organon’s announcement. Sun Pharma plans to fund the purchase through a mix of available cash and committed bank financing.
Deal Overview: Structure, Value and Strategic Intent
Sun Pharma will acquire 100% of Organon, a US-based pharmaceutical company that was spun off from Merck & Co. in 2021. Organon focuses on women’s health, biosimilars, and established medicines, making it a complementary fit for Sun Pharma’s existing portfolio.
The total deal value of $11.75 billion includes Organon’s outstanding debt, making it one of the most significant outbound acquisitions by an Indian company in recent years.
Sun Pharma shares reacted positively to the Organon announcement, with the stock jumping over 4% and touching an intraday high of around INR 1,688 on the NSE after the deal was disclosed. Other reports said the stock rose as much as 5% to Rs 1,704, and in some intraday trading it even climbed to about INR 1,750.65, suggesting investors welcomed the overseas expansion despite the large price tag.
Organon reported revenue of US$ 6.2 billion for the year ended December 2025, along with adjusted EBITDA of US$ 1.9 billion. The company also carried debt of about US$ 8.6 billion, a key factor in the overall deal value.
Why the Organon deal matters
This takeover could become a defining overseas move for Sun Pharma, which is already India’s largest drugmaker by market value. By bringing Organon into its portfolio, Sun Pharma gets a bigger footprint in the US market and a stronger position in higher-margin therapy areas.
The deal also reflects a broader trend of Indian pharmaceutical firms moving more aggressively into global branded and speciality medicines. For investors, the immediate question is how smoothly Sun Pharma can integrate Organon’s business and manage the debt load that comes with it.
What happens next
The transaction is now moving into the regulatory and shareholder approval phase, which will determine whether it closes on schedule in early 2027. Until then, the market will likely watch for further details on financing, integration plans and any reaction from Organon shareholders.
In simple terms, this is a large and strategic bet by Sun Pharma to scale up globally. The acquisition, if completed, could reshape the company’s overseas business and strengthen its long-term international ambitions.
